Biovie is trading 5% higher at $1.30 on October 26, 2026; available reporting does not establish a reason for the move. - Broader markets are higher: the S&P 500 is up 0.88% and the Nasdaq Composite is up 1.26%; no source explicitly links their gains to Biovie’s move. - Biovie announced an October 26 invitation to present Long COVID trial data at an NIH-hosted workshop, but reporting does not establish the announcement as the reason for the move.